A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease

Overview

To investigate whether 24 months of idebenone may reduce the progression from Prodromal Parkinson disease (PPD) to Parkinson disease (PD).

Full Title of Study: “A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 1, 2022

Detailed Description

Number of people suffered from Parkinson disease (PD) is increasing every year. Contemporary medication has little neuroprotective effect, which may due to delayed treatment as over 50% neurons have lost when clinical diagnosed PD emerges. The concept of Prodromal Parkinson disease (PPD) is emphasized as it has become evident that there are several risk and clinical markers may occur years before the cardinal motor symptoms which allow clinical diagnosis. Rapid eye movement (REM) sleep behavior disorder and olfactory dysfunction are the most common PPD, and more than one third of patients may progress to PD and other neurodegenerative diseases. Mitochondrial injury is one of the pathogenesis of PD. Thus we design this trial to investigate whether idebenone, potent coenzyme Q10 analogue, could protect PPD develops into PD.

Interventions

  • Drug: Idebenone
    • 30mg tablets three times a day
  • Drug: Placebo oral tablet
    • placebo tablets three times a day

Arms, Groups and Cohorts

  • Active Comparator: Group 1: idebenone
    • Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
  • Placebo Comparator: Group 2: placebo
    • Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months

Clinical Trial Outcome Measures

Primary Measures

  • Clinical diagnosis of parkinson disease
    • Time Frame: 24 months
    • based on Movement Disorder Society (MDS) Research Criteria for Prodromal Parkinson’s Disease in 2015

Secondary Measures

  • Dopamine transporter positron emission tomography (DAT-PET) change
    • Time Frame: 12 month and 24 month
    • diminishment of striatal DAT-PET
  • Quantitative motor testing change
    • Time Frame: 24 months
    • Unified Parkinson Disease Rating Scale, Part III

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects are voluntary to participate and have signed informed consent – Diagnosed as Rapid Eye movement (REM) Sleep Behavior Disorder by polysomnography Exclusion Criteria:

  • Subjects are pregnant, breastfeeding, or want to get pregnant or breastfeeding in 2 years – Subjects have history of allergy to idebenone – Difficulty to communicate – Suffering from neurodegenerative diseases – Having obvious brain imaging abnormalities (eg. severe brain atrophy, malformation, softening lesions, cerebrovascular disease, intracranial occupancy, giant large benign lesions, etc.) – Having severe mental illness (eg. schizophrenia, manic depression, and severe depression) – Long-term use of clonidine, dopamine antagonists, and serotonin reuptake inhibitors – Suffering from other severe medical conditions – Having difficulty in moving and are unable to come to the hospital – Having claustrophobia – Having contraindications to MRI tests – Having history of olfactory disorders greater than 10 years – Having history of color vision disorders greater than 10 years – Life expectancy less than 2 years – Having other situations which researchers consider is inappropriate to participate in this study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Collaborator
    • Peking Union Medical College Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Baorong Zhang, MD, Study Chair, Second Affiliated Hospital of Zhejiang University School of Medicine
  • Overall Contact(s)
    • Baorong Zhang, MD, +86 13958167260, brzhang@zju.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.